(CercleFinance.com) – Oddo BHF maintains its outperform rating on Novo Nordisk shares with an unchanged price target of 800 DKK.
The analyst recalls that Novo Nordisk communicated yesterday, during the session, positive topline results from the phase 3a COMBINE 3 study evaluating IcoSema in the treatment of type 2 diabetes.
Oddo BHF believes that if these first results ‘do not represent a surprise’, the trial remains a success.
Thus, ‘the group is starting the year on a very positive note regarding an important asset in its pipeline’, underlines the broker.
Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
This is a Smartvoice article: see legal notices